Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tubulin polymerization-IN-14 (Compound 20a) 是一种微管蛋白聚合抑制剂(IC 50 = 3.15 μM) ,具有强大的抗血管和抗癌活性,包括诱导癌细胞凋亡。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | Tubulin polymerization-IN-14 (Compound 20a) is a tubulin polymerization inhibitor (IC 50 = 3.15 μM) that exhibits potent anti-vascular and anticancer activities including cancer cell apoptosis [1]. |
体外活性 | Tubulin polymerization-IN-14 (Compound 20a) binds to the colchicine binding site on tubulin [1]. Tubulin polymerization-IN-14 (0-1 μM; 72 h) inhibits cancer cell growth [1]. Tubulin polymerization-IN-14 (5-20 nM; 48 h) arrests K562 cell cycle at G2/M phase, significantly induces cell apoptosis in K562 cells in a concentration-dependent manner, and induces mitochondrial membrane potential (MMP) collapse and mitochondrial dysfunction in K562 cells [1]. Tubulin polymerization-IN-14 (5-20 nM; 24 h) significantly decreases wound closure and capillary-like tubules formation in a concentration-dependent manner in HUVECs [1]. Cell Proliferation Assay [1] Cell Line: K562 cells Concentration: 0-1 μM Incubation Time: 72 h Result: Showed anti-proliferative activity with an IC 50 of 0.01 ± 0.001 μM against K562 cells. Cell Cytotoxicity Assay [1] Cell Line: HepG2, HCT-8, MDA-MB-231 and HFL-1 cells Concentration: 0-1 μM Incubation Time: 72 h Result: Showed cytotoxic activities with IC 50 s of 0.019 ± 0.002, 0.021 ± 0.003, 0.02 ± 0.001 and 0.118 ± 0.007 μM against HepG2, HCT-8, MDA-MB-231 and HFL-1 cells, respectively. Cell Cycle Analysis [1] Cell Line: K562 cells Concentration: 5 nM, 10 nM and 20 nM Incubation Time: 48 h Result: 9.40%, 11.54% and 15.28% of cells were arrested at G2/M phase at 5, 10 and 20 nM, respectively. Apoptosis Analysis [1] Cell Line: K562 cells Concentration: 5 nM, 10 nM and 20 nM Incubation Time: 48 h Result: Compared to the percentage of apoptosis cells in control group (3.25%), the total percentage of the early (Annexin-Vt/PI) and late (Annexin-Vt/PIt) apoptosis cells were 10.46%, 48.55% and 62.26% after being treated at 5, 10, and 20 nM for 48 h, respectively. Cell Migration Assay [1] Cell Line: HUVECs Concentration: 5 nM, 10 nM and 20 nM Incubation Time: 24 h Result: After exposed to compound at 5, 10, and 20 nM for 24 h, cells migrated into 67.6%, 55.3% and 49.2% of the wound area, respectively. |
体内活性 | Tubulin polymerization-IN-14 (Compound 20a) (15 and 30 mg/kg; i.v.; daily for 21 days) displays obvious and dose-dependent antitumor effect with no significant toxicity in the liver tumor allograft mouse model [1]. Animal Model: Five-week-old male ICR mice, liver tumor allograft model [1] Dosage: 15 and 30 mg/kg Administration: Intravenous injection, daily for 21 days Result: The decrease in tumor weight reached 68.7% at doses of 30 mg/kg per day at 21 days after initiation of treatment as compared to vehicle without obvious loss of body weight. |
分子量 | 290.74 |
分子式 | C15H15ClN2O2 |
CAS No. | 2417134-05-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tubulin polymerization-IN-14 2417134-05-3 Inhibitor inhibitor inhibit